Efficacy of triplet regimen antiemetic therapy for chemotherapy‐induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single‐shot palonosetron and consecutive‐day granisetron for CINV in a randomized, single‐blinded crossover study. (23rd December 2014)

• Record Type: Journal Article
• Authors: Kimura, Hiroaki; Yamamoto, Norio; Shirai, Toshiharu; Nishida, Hideji; Hayashi, Katsuhiro; Tanzawa, Yoshikazu; Takeuchi, Akihiko; Igarashi, Kentaro; Inatani, Hiroyuki; Shimozaki, Shingo; Kato, Takashi; Aoki, Yu; Higuchi, Takashi; Tsuchiya, Hiroyuki
• Is Part Of: Cancer medicine. Volume 4:Number 3(2015:Mar.)
• Page Start: 333
• Page End: 341
• Publication Date: 2014-12-23
• Subjects: Antiemetic therapy -- bone and soft tissue sarcoma -- chemotherapy‐induced nausea and vomiting -- crossover trial -- granisetron -- palonosetron; 616.994005
• DOI: 10.1002/cam4.373
• Languages: English
• ISSNs: 2045-7634

Abstract

Abstract: The first aim of this study was to evaluate combination antiemetic therapy consisting of 5‐HT3 receptor antagonists, neurokinin‐1 receptor antagonists (NK‐1RAs), and dexamethasone for multiple high emetogenic risk (HER) anticancer agents in bone and soft tissue sarcoma. The second aim was to compare the effectiveness of single‐shot palonosetron and consecutive‐day granisetron in a randomized, single‐blinded crossover study. A single randomization method was used to assign eligible patients to the palonosetron or granisetron arm. Patients in the palonosetron arm received a palonosetron regimen during the first and third chemotherapy courses and a granisetron regimen during the second and fourth courses. All patients received NK‐1RA and dexamethasone. Patients receiving the palonosetron regimen were administered 0.75 mg palonosetron on day 1, and patients receiving the granisetron regimen were administered 3 mg granisetron twice daily on days 1 through 5. All 24 patients in this study received at least 4 chemotherapy courses. A total of 96 courses of antiemetic therapy were evaluated. Overall, the complete response CR rate (no emetic episodes and no rescue medication use) was 34%, while the total control rate (a CR plus no nausea) was 7%. No significant differences were observed between single‐shot palonosetron and consecutive‐day granisetron. Antiemetic therapy with a 3‐drug combination was not sufficient to control chemotherapy‐induced nausea and vomiting (CINV) during chemotherapy with multiple HER agents for bone and soft tissue sarcoma. This study also demonstrated that consecutive‐day granisetron was not inferior to single‐shot palonosetron for treating CINV. Abstract : Antiemetic therapy with a 3‐drug combination was not sufficient to control chemotherapy‐induced nausea and vomiting (CINV) during combination chemotherapy for bone and soft tissue sarcoma patients. No significant differences were observed between single‐shot palonosetron and consecutive‐day granisetron administration for CINV.